Mevopur™ Healthcare Bio-based Polymer Solutions for Medical Devices and Pharmaceutical Packaging Manufacturers of medical devices and pharmaceutical packaging are increasingly faced with the challenge of integrating sustainability into the design of their products. As part of our commitment, we publish Avient’s Mevopur™ product policy and use limitations to assist customers in their product selection. For more detailed information on Mevopur uses and restrictions see www.avient.com/healthcare-use-limitations-mevopur-products or contact your Avient sales representative. 1.844.4AVIENT www.avient.com

It has already started producing useful data and we will use this to continue to develop new and unique masterbatch solutions with proven science behind how they perform during recycling processes, offering customers a portfolio certified by the laboratory. We expect to introduce more products throughout 2021 as new data is generated. Sources: 1)    https://verpackungsgesetz-info.de/wp-content/uploads/2021/06/twopager-packaging-amendment-1.pdf 2)    https://ec.europa.eu/commission/presscorner/detail/en/IP_18_3846 3)    https://verpackungsgesetz-info.de/en/#verpackungsgesetz

It has already started producing useful data and we will use this to continue to develop new and unique masterbatch solutions with proven science behind how they perform during recycling processes, offering customers a portfolio certified by the laboratory. We expect to introduce more products throughout 2021 as new data is generated. Sources: 1)    https://verpackungsgesetz-info.de/wp-content/uploads/2021/06/twopager-packaging-amendment-1.pdf 2)    https://ec.europa.eu/commission/presscorner/detail/en/IP_18_3846 3)    https://verpackungsgesetz-info.de/en/#verpackungsgesetz

Mevopur™ Healthcare Functional Additives Mevopur™ Healthcare Bio-based Polymer Solutions Mevopur™ Healthcare Colorants and Formulations

Mevopur™ Healthcare Functional Additives Mevopur™ Healthcare Colorants and Formulations Mevopur™ Healthcare Bio-based Polymer Solutions

Buyer acknowledges that information in Seller’s marketing materials, technical data sheets and other descriptive publications distributed or published on its websites may vary from time to time without notice. Buyer acknowledges that Seller has furnished to Buyer Safety Data Sheets, which include warnings together with safety and health information concerning the Product and/or the containers for such Product. Data Protection.

Safety & Health Indemnity. Buyer acknowledges that Seller has furnished to Buyer Material Safety Data sheets, which include warnings together with safety and health information concerning the Product and/or the containers for such Product. การรบัรองความปลอดภยั และสุขอนามยั ผูซื้7 อรบัทราบวา่ ผูข้ายไดส่้งมอบเอกสารขอ้มูลความปลอดภยั (Material Safety Data sheets) ใหแ้ก่ผูซื้7 อแลว้ ซึ(งรวมถึงขอ้ควรระวงัต่างๆ พรอ้มดว้ยขอ้มูลความปลอดภยัและสุขอนามยัเกี(ยวกบัสินคา้ และ/หรือบรรจุภณัฑข์องสินคา้ดงักล่าว ผูซ้ื7 อจะเผยแพรข่อ้มลูดงักลา่วเพื(อแจง้ ขอ้ควรระวงัเกี(ยวกบัอนัตรายต่างๆ ที(อาจเกดิขึ7 นแกบุ่คคลที( ผูซื้7 อพึงคาดหมายไดต้ามสมควรวา่อาจไดร้บัอนัตรายดงักล่าว รวมถงึ แต่ไม่จาํกดัเพียง ลกูจา้ง ตวัแทน ผูร้บัจา้ง และลูกคา้ของผูซื้7 อ ผูซ้ื7 อจะชดใชค้วามเสียหาย แกต้่าง และคุม้ครองผูข้ายใหป้ลอดพน้จากความรบัผิดทั7งปวงอนัเกิดจาก หรือเกี(ยวเนื(องกบัการที(ผูซื้7 อมิไดเ้ผยแพร่ขอ้มลูดงักล่าว รวมถึง แต่ไม่จาํกดัเพียง ความรบัผิดต่อการบาดเจ็บ การเจ็บป่วย การเสียชีวติ และความเสียหายต่อทรพัยสิ์น และค่าใชจ่้ายในการตรวจสอบ การฟ้องรอ้งดาํเนินคดี และค่าทนายความตามสมควร 11.

 Strong past performance demonstrates that our strategy and execution are working  Megatrends and emerging opportunities align with our strengths  Innovation and services provide differentiation, incremental pricing power, and competitive advantage  Strong and proven management team driving growth and performance  Addressable market exceeds $40 billion 1 Schedule I Reconciliation of Non-GAAP Financial Measures (Unaudited) (Dollars in millions, except per share data) Below is a reconciliation of non-GAAP financial measures to the most directly comparable measures calculated and presented in accordance with U.S. ��PolyOne Investor Presentation�Goldman Sachs 2014 US Emerging / SMID Cap Growth Conference�New York, NY�November 20, 2014�� Forward-Looking Statements Use of Non-GAAP Measures PolyOne Commodity to Specialty Transformation PolyOne�At A Glance Mix Shift Highlights Specialty Transformation Confirmation of Our Strategy Strategy and Execution Drive Results Proof of Performance & 2015 Goals 32% Adjusted EPS CAGR from 2011 Innovation Drives Earnings Growth A Rich Pipeline of Opportunity Megatrends Aligned with Key End Markets Debt Maturities & Pension Funding – 9/30/14 Free Cash Flow and Strong Balance Sheet �Fund Investment / Shareholder Return PolyOne Core Values Why Invest In PolyOne? Non GAAP Rec - 11 5 14.pdf Sidoti & Company non-GAAP Rec

GENOMIC DIAGNOSTIC DEVICE MANUFACTURER I N - V I T R O D I AG N O S T I C ( I V D ) D E V I C E MEVOPURTM Laser-Transmitting and Laser-Absorbing Pre-color Solution AVIENT SOLUTION • Customized solutions - Quality-by-Design (QdB) approach • Optimized pigment / additive selection – good distribution in final part minimizes welding failure • Mitigated contamination and extractable risk on incoming raw material with control based on fingerprinting • Ensured uninterrupted supply from multiple ISO13485-2016 certified sites • Minimized risk of change with change control agreements WHY AVIENT KEY REQUIREM ENTS P R O D U C T I V I T Y & Q UA L I T Y • Good weldability, low rejection rate • Solutions in wide range of polymers, colors and transparency • Pre-tested ingredients to biocompatibility and extractable metals LEARN MORE https://www.avient.com/products/polymer-additives/performance-enhancement-additives/mevopur-functional-additives

As part of our commitment, we publish Avient’s Mevopur™ product policy and use limitations to assist customers in their product selection. Please be aware that there are certain applications Avient’s Mevopur products have not been designed for, nor are they promoted or intended for use in: including, but not limited to long-term or permanent implants, birth control devices, or plastic surgery. For more detailed information on Mevopur uses and restrictions see www.avient.com/healthcare-use-limitations-mevopur-products or contact your Avient sales representative. 1.844.4AVIENT www.avient.com